Avid Bioservices Inc (CDMO)

[cjgaddy]

I think when CEO Steve King on Wed. at Wedbush/NYC said the following about the upcoming Sept 7th plenary talk at ASCO-Thoracic/Chicago by UTSW’s Dr. David Gerber at the ASCO/ASTRO Chicago Multidisciplinary Symposium in Thoracic Oncology, he was telling us that the 2nd-Line NSCLC update on MOS (whether reached in the Bavi arms by then or not) will include the appropriate trial statistics, such as hazard ratios and P-values…

SK/Slide16 8-15-12: “With this (2nd-Line NSCLC) data in hand, we now have a number of events to look forward to… We have 2 Late-Breaking presentations coming up… Our goal in the Sept. 7th Chicago data presentation is to be able to talk a little bit more about the (2nd-Line NSCLC) MOS and where we’re at evaluating that in both Bavi arms. Even though we haven’t reached MOS, and certainly may not have reached it by then, we still will be able to talk a little bit more about where we’re at in that process. We’ll also be able to talk more about how the statistics in the trial are trending, and how we put those kinds of events together into our thinking about a Phase III trial design.”
http://tinyurl.com/8mhrtld

• Sept7: Chicago Symposium in Thoracic Oncology http://tinyurl.com/9vt2vbo - 1:40-1:50pm Dr. David Gerber (UTSW), Late-breaker PLENARY talk on Bavi+Doce 2nd-Line NSCLC Trial
• Sept29: ESMO 2012 Congress (Eur. Society for Medical Oncology), Vienna, Austria http://tinyurl.com/9zj2ot4 - per 8-15-12/Wedbush, Late-Breaker on Bavi 2nd-Line NSCLC Ph2 Trial (incl. MOS status for both Bavi arms)